Publications by authors named "Lisa Anne Carey"
Article Synopsis
- - Cancer and cardiovascular diseases are leading causes of death and health issues globally, with breast cancer treatments increasing survivor rates but also introducing long-term side effects.
- - New breast cancer drugs, like elacestrant and tucatinib, show effectiveness but can cause cardiovascular toxicities that need to be managed carefully.
- - Effective management of these side effects requires quick diagnosis and a collaborative approach with specialists known as cardio-oncologists.
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10-15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menopausal women and is associated with significant psychological and treatment-related burdens, including financial toxicity.
View Article and Find Full Text PDFBackground: Breast cancer (BC) is a leading cause of morbidity, mortality, and disability for women worldwide. There is substantial variation in treatment outcomes, which is function of multiple variables, including access to treatment. Treatment standards can promote quality and improve survival; thus, their development should be a priority for the cancer-control planning.
View Article and Find Full Text PDFBackground: We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.
Methods: Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC.